BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study.

COI Statement

L.E.R. has served as a consultant for AbbVie, Ascentage, AstraZeneca, BeiGene, Janssen, Loxo Oncology, Pharmacyclics, Pfizer, and TG Therapeutics; is a member of a data safety monitoring committee (DSMC) for Ascentage; served as a CME speaker for DAVA, Curio, Medscape, and PeerView; holds a minority ownership interest in Abbott Laboratories; received travel support from Loxo Oncology; and received research funding (paid to the institution) from Adaptive Biotechnologies, AstraZeneca, Genentech, AbbVie, Pfizer, Loxo Oncology, Aptose Biosciences, Dren Bio, and Qilu Puget Sound Biotherapeutics. Y.H. is employed by Vinzent Strategies, which received funding from AstraZeneca for statistical analysis services. A.T. and A.R.M. are employees of and own stock in AstraZeneca. M.C.T. has served on consultancy/advisory boards for AbbVie, AstraZeneca, BeiGene, Janssen, and Loxo Oncology; received research funding (paid to the institution) from AbbVie, AstraZeneca, BeiGene, GenMab, Nurix Therapeutics, and Genentech; received travel support from GenMab, Nurix Therapeutics, and Dava Oncology; and received honoraria from PeerView Medical Institute, Dava Oncology, Philips Group Oncology Communications, MJH Life Sciences, Intellisphere LLC, Clinical Care Options, and Mashup Media.

References:

• Eichhorst B., Ghia P., Niemann C. U., et al., “ESMO Clinical Practice Guideline Interim Update on New Targeted Therapies in the First Line and at Relapse of Chronic Lymphocytic Leukaemia,” Annals of Oncology 35, no. 9 (2024): 762–768.
• Seymour J. F., Kipps T. J., Eichhorst B., et al., “Venetoclax‐Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia,” New England Journal of Medicine 378, no. 12 (2018): 1107–1120.
• Munir T., Brown J. R., O'Brien S., et al., “Final Analysis From RESONATE: Up to Six Years of Follow‐Up on Ibrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,” American Journal of Hematology 94, no. 12 (2019): 1353–1363.
• Simon F. and Bohn J. P., “Next‐Generation Sequencing‐Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),” Current Oncology Reports 25, no. 10 (2023): 1181–1189.
• Davids M. S., Telford C., Abhyankar S., Waweru C., and Ringshausen I., “Matching‐Adjusted Indirect Comparisons of Safety and Efficacy of Acalabrutinib Versus Other Targeted Therapies in Patients With Treatment‐Naïve Chronic Lymphocytic Leukemia,” Leukemia & Lymphoma 62, no. 10 (2021): 2342–2351.